Abstract
Background: The National Psoriasis Foundation recommends body surface area (BSA) involvement of ≤1% as an ideal response after 12 weeks of psoriasis therapy. BSA involvement of ≤3% or improvement from baseline of ≥75% are acceptable goals after 12 treatment weeks. This post hoc analysis examines achievement of BSA targets in patients with moderate-to-severe psoriasis receiving the interleukin-17 receptor A antagonist brodalumab.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
